Method for evaluating curative effect of compound glutamine formula on diarrhea-predominant irritable bowel syndromes

Abstract

The invention discloses a method for evaluating the curative effect of a compound glutamine formula on diarrhea-predominant irritable bowel syndromes. The method mainly comprises the following steps:I, establishing a diarrhea-predominant irritable bowel syndrome animal model; II, performing medicine application; III, performing index detection and scoring (including general clinical observation,excrement and urine detection, intestinal motility influence observation, visceral sensitivity evaluation and colon tissue pathological examination); and IV, performing counting and evaluation. With the adoption of the scheme, the compound glutamine formula with different dosage forms and different use doses can be accurately evaluated in the aspect of treating diarrhea-predominant irritable bowelsyndromes; and preposed basis and valuable guidance are provided for subsequent continuous optimization of dosage form rationality and dosage use of the compound glutamine formula, and further betterin-depth clinical treatment and research of the diarrhea-predominant irritable bowel syndromes and continuous clarification of IBS curative effects.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a method for evaluating the curative effect of a compound glutamine prescription on diarrhea-type irritable bowel syndrome. Background technique [0002] Irritable bowel syndrome (IBS) is a common chronic intestinal dysfunction disease. Its clinical manifestations are abdominal pain, abdominal distension, and changes in defecation habits and shapes. Most of them are intermittent attacks without organic lesions. Clinically, IBS is often further divided into diarrhea-predominant IBS and constipation-predominant IBS. Due to the unclear etiology and complex pathogenesis of IBS, although there are many treatment methods, the curative effects are not exact. [0003] Compound Glutamine Enteric-Coated Capsules was developed by the applicant (Di'ao Group Chengdu Pharmaceutical Co., Ltd.), and it is used to treat acute and chronic intestinal diseases and intestinal dysfunction (such as intestinal ...

AI Technical Summary

Problems solved by technology

[0004] However, the above-mentioned method is a clinical observation and quantitative test, and does not analyze the different compound glutamine formulations (comprising compound glutamine enteric-coated capsules and compound glutamine gastric-coated capsules) and dosage usage. Accurate evaluation of the curative effect and advantages of compound glutamine prescription on diarrhea-predominant irritable bowel syndrome can only provide a treatment option, and cannot provide a basis for optimizing the treatment and research of compound glutamine prescription on diarrhea-predominant irritable bowel syndrome. provide further guidance

Images